Efavirenz Mitigates Dyslipidemia and Attenuates Ulcerative Colitis through Gut Microbiota Modulation.
Saved in:
| Title: | Efavirenz Mitigates Dyslipidemia and Attenuates Ulcerative Colitis through Gut Microbiota Modulation. |
|---|---|
| Authors: | Wang W; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.; Department of Pharmacy, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China., Niu X; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.; Department of Pharmacy, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China., Li S; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China., Cheng B; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China., Cheng L; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China., Yang C; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China., Xu X; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.; Ribopeutic Inc., Guangzhou International Bio Island, Guangzhou 510005, China., Chang S; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China., Wang C; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China., Liu S; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.; State Key Laboratory of Organ Failure Research, Guangdong Provincial Institute of Nephrology, Southern Medical University, Guangzhou 510515, China.; MOE Key Laboratory of Infectious Diseases Research in South China, Southern Medical University, Guangzhou 510515, China. |
| Source: | ACS infectious diseases [ACS Infect Dis] 2026 Jun 12; Vol. 12 (6), pp. 2136-2148. Date of Electronic Publication: 2026 Jun 01. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: ACS Publications Country of Publication: United States NLM ID: 101654580 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2373-8227 (Electronic) Linking ISSN: 23738227 NLM ISO Abbreviation: ACS Infect Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 42225309 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Efavirenz Mitigates Dyslipidemia and Attenuates Ulcerative Colitis through Gut Microbiota Modulation. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Wang+W%22">Wang W</searchLink>; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.; Department of Pharmacy, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China.<br /><searchLink fieldCode="AU" term="%22Niu+X%22">Niu X</searchLink>; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.; Department of Pharmacy, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China.<br /><searchLink fieldCode="AU" term="%22Li+S%22">Li S</searchLink>; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.<br /><searchLink fieldCode="AU" term="%22Cheng+B%22">Cheng B</searchLink>; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.<br /><searchLink fieldCode="AU" term="%22Cheng+L%22">Cheng L</searchLink>; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.<br /><searchLink fieldCode="AU" term="%22Yang+C%22">Yang C</searchLink>; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.<br /><searchLink fieldCode="AU" term="%22Xu+X%22">Xu X</searchLink>; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.; Ribopeutic Inc., Guangzhou International Bio Island, Guangzhou 510005, China.<br /><searchLink fieldCode="AU" term="%22Chang+S%22">Chang S</searchLink>; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.<br /><searchLink fieldCode="AU" term="%22Wang+C%22">Wang C</searchLink>; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.<br /><searchLink fieldCode="AU" term="%22Liu+S%22">Liu S</searchLink>; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.; State Key Laboratory of Organ Failure Research, Guangdong Provincial Institute of Nephrology, Southern Medical University, Guangzhou 510515, China.; MOE Key Laboratory of Infectious Diseases Research in South China, Southern Medical University, Guangzhou 510515, China. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101654580%22">ACS infectious diseases</searchLink> [ACS Infect Dis] 2026 Jun 12; Vol. 12 (6), pp. 2136-2148. <i>Date of Electronic Publication: </i>2026 Jun 01. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22ACS+Publications%22">ACS Publications </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101654580 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2373-8227 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2223738227%22">23738227 </searchLink><i>NLM ISO Abbreviation: </i>ACS Infect Dis <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42225309 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1021/acsinfecdis.6c00330 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 2136 Titles: – TitleFull: Efavirenz Mitigates Dyslipidemia and Attenuates Ulcerative Colitis through Gut Microbiota Modulation. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Wang W – PersonEntity: Name: NameFull: Niu X – PersonEntity: Name: NameFull: Li S – PersonEntity: Name: NameFull: Cheng B – PersonEntity: Name: NameFull: Cheng L – PersonEntity: Name: NameFull: Yang C – PersonEntity: Name: NameFull: Xu X – PersonEntity: Name: NameFull: Chang S – PersonEntity: Name: NameFull: Wang C – PersonEntity: Name: NameFull: Liu S IsPartOfRelationships: – BibEntity: Dates: – D: 12 M: 06 Text: 2026 Jun 12 Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 2373-8227 Numbering: – Type: volume Value: 12 – Type: issue Value: 6 Titles: – TitleFull: ACS infectious diseases Type: main |
| ResultId | 1 |
